In the B‐cell lymphoma/leukemia, multiple myeloma oncogene 1 (MUM1) can upregulate the expression of CXCL9 by activating its promoter in cooperation with PU.1, leading to poor prognosis of B‐cell malignancy 21. Here, IRF4 is linked to B-cell non-Hodgkin lymphoma.